DrugBiological
Tozorakimab clinical trials
Also written MEDI3506.
- studies test it
- 13
- open now
- 2
- in phase 3
- 4
- first study started
- 2017
Keep track of what changes. Save the tozorakimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
13 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 6
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 0
Studies
Open first, then newest update. How each study uses tozorakimab is read from its arms, and is right about nine times in ten.
Testing it · 13
- Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental OxygenRecruitingPhase 3AstraZenecaNCT05624450Written as Tozorakimab
- Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled CorticosteroidsRecruitingPhase 2AstraZenecaNCT06932263Written as Tozorakimab
- Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of ExacerbationsCompletedPhase 3AstraZenecaNCT06040086Written as Tozorakimab
- A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated EosinophilsCompletedPhase 2AstraZenecaNCT06897748Written as Tozorakimab
- Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of ExacerbationsCompletedPhase 3AstraZenecaNCT05166889Written as Tozorakimab
- Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.CompletedPhase 3AstraZenecaNCT05158387Written as Tozorakimab
- A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic BronchitisCompletedPhase 2AstraZenecaNCT04631016Written as Tozorakimab
- A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy VolunteersCompletedPhase 1AstraZenecaNCT06304961Written as Tozorakimab
- A Phase 2b Diabetic Kidney Disease StudyCompletedPhase 2AstraZenecaNCT04170543Written as MEDI3506
- Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe AsthmaCompletedPhase 2AstraZenecaNCT04570657Written as MEDI3506
- Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic DermatitisCompletedPhase 2AstraZenecaNCT04212169Written as MEDI3506
- Pharmacokinetics, Immunogenicity, Safety and Tolerability of MEDI3506 in Health Chinese ParticipantsCompletedPhase 1AstraZenecaNCT05070312Written as MEDI3506
- Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese ParticipantsCompletedPhase 1MedImmune LLCNCT03096795Written as MEDI3506
Given in every arm · 1 — tozorakimab is usual care beside what is tested
Codes
What other systems call tozorakimab · ClinicalTrials.gg INT017477
- UNII (FDA) OHZ2MEL7FDTOZORAKIMABOne source FDA
- NCI Thesaurus C179129TozorakimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | OHZ2MEL7FD | TOZORAKIMAB | One source FDA |
| NCI Thesaurus | C179129 | Tozorakimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.